Predicting and remediating immunogenicity in lead antibody candidates
14 Apr 2025
Lead Identification & Optimization
- What factors influence the immunogenicity of therapeutic antibodies in vivo?
- How useful are in silico and in vitro methods in predicting immunogenicity risk?
- What types of antibody engineering strategies can mitigate immunogenicity risk in lead compounds?
- How can retrospective analyses of clinical anti-drug antibody responses be leveraged to refine immunogenicity risk predictions?
- What do you consider to be ‘Best Practices’ within immunogenicity risk assessment and testing when advancing therapeutic antibodies to the clinic? And what do you foresee as the future direction of regulating large molecule compounds in this regard?
Industry Expert
